The Canadian Cancer Action Network (CCAN) and the CADTH pan-Canadian Oncology Drug Review (pCODR) program are pleased to continue our collaboration with the introduction of the Health Technology Assessment Patient Engagement Navigator (HTAPEN) position to assist the cancer patient community in navigating and understanding health technology assessment (HTA) in Canada.
At this time, we are pleased to announce that Adam Waiser has been hired by CCAN to lead this initiative into early 2017. In his role as HTAPEN, Adam will assist the patient community with their understanding of the pCODR process and provide the support required to optimize patient submissions for cancer drugs under review, as well as exploring, developing, and supporting opportunities for enhanced cancer patient community engagement and knowledge translation.
Funded by the Canadian Partnership Against Cancer, with in-kind funding provided by CADTH and CCAN, this exciting joint initiative reflects a shared commitment to address the expressed needs of patient groups in Canada and to continue to collaboratively explore innovative ways to best support and engage the patient community.
We believe that patient input on drug reviews is important to the pCODR process, ensuring that the values and experiences of patients living with cancer and undergoing treatment, as well as their caregivers, are substantively considered.
To learn more about the HTAPEN initiative, we would encourage you to contact Adam directly at hta@canceraction.ca.